Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-15,215
Closed -$379K 144
2025
Q4
$379K Sell
15,215
-30,667
-67% -$773K 0.26% 96
2025
Q3
$1.17M Buy
45,882
+3,985
+10% +$98.4K 0.74% 35
2025
Q2
$1.02M Buy
+41,897
New +$977K 0.68% 45
2023
Q3
Sell
-5,817
Closed -$213K 194
2023
Q2
$213K Sell
5,817
-938
-14% -$36.5K 0.17% 172
2023
Q1
$276K Buy
6,755
+616
+10% +$26.6K 0.21% 150
2022
Q4
$315K Buy
6,139
+418
+7% +$20K 0.24% 136
2022
Q3
$250K Sell
5,721
-1,157
-17% -$56.2K 0.22% 145
2022
Q2
$361K Sell
6,878
-1,137
-14% -$57.9K 0.29% 118
2022
Q1
$415K Buy
8,015
+1,671
+26% +$86.7K 0.28% 113
2021
Q4
$375K Sell
6,344
-123
-2% -$6.09K 0.26% 129
2021
Q3
$278K Sell
6,467
-4,959
-43% -$220K 0.22% 139
2021
Q2
$447K Buy
11,426
+1,326
+13% +$51.6K 0.34% 96
2021
Q1
$366K Sell
10,100
-1,394
-12% -$49.5K 0.29% 108
2020
Q4
$423K Buy
+11,494
New +$422K 0.35% 90

Other funds holding PFE

Renasant Bank's PFE Position: Q1 2026 in Review

Renasant Bank sold out of Pfizer (PFE) in Q1 2026, closing a stake of 15,215 shares — an estimated $379K sold.

Renasant Bank first reported a position in PFE in Q4 2020 and held it in 14 quarters. The position peaked at $1.17M in Q3 2025. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Renasant Bank reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Renasant Bank sold 15,215 Pfizer shares in Q1 2026, an estimated $379K.
  • Renasant Bank first reported a position in Pfizer in Q4 2020 and held it in 14 quarters.
  • Renasant Bank's Pfizer position peaked at $1.17M in Q3 2025.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Renasant Bank's 13F filing for Q1 2026, filed 29 Apr 2026.